VJNeurology is committed to improving our service to you

Share this video  

VJNeurology is committed to improving our service to you

EAN 2022 | The burden of migraine: from individuals to society

Messoud Ashina, MD, PhD, University of Copenhagen, Copenhagen, Denmark, discusses the burden of migraine and cost/health implications associated with sub-optimal migraine management. Migraine is a common condition with a high global prevalence. If not treated, migraine will significantly impact the patient’s quality of life. Still, the consequences of sub-optimal migraine management are not limited to individuals but also affect society. Migraine usually strikes during the formative and most productive periods of patients’ lives, impacting work activity, family, and social life. The burden of migraine on society includes direct costs associated with medical care and indirect costs caused by absence from work and reduced productivity. Although there have been significant efforts in migraine education and awareness, migraine continues to be underdiagnosed and undertreated. Optimization of diagnosis and treatment could help reduce the migraine burden. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.


Messoud Ashina is a consultant, speaker, or scientific advisor for AbbVie, Amgen, Eli Lilly, Lundbeck, Novartis, Pfizer and Teva. Messoud Ashina is a primary investigator for ongoing AbbVie, Amgen and Lundbeck trials. Messoud Ashina has no ownership interest and does not own stocks of any pharmaceutical company.